Fig. 2From: Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in BandiagaraAnti FVO-AMA1 IgG titres. Individual data points are plotted as well as a box indicating median and 25 and 75 % quantiles. Same symbol and color refer to same individuals within treatment groupsBack to article page